Tyrphostin AG1478 inhibits encephalomyocarditis virus and hepatitis C virus by targeting phosphatidylinositol 4-kinase IIIα
Publication date
2016-09
Authors
Dorobantu, C.M.
Harak, Christian
Klein, Rahel
van der Linden, Lonneke
Strating, Jeroen R P M
van der Schaar, Hilde
Lohmann, Volker
van Kuppeveld, Frank J M
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Encephalomyocarditis virus (EMCV), like hepatitis C virus (HCV), requires phosphatidylinositol 4-kinase IIIα (PI4KA) for genome replication. Here, we demonstrate that tyrphostin AG1478, a known EGFR inhibitor, also inhibits PI4KA activity, both in vitro and in cells. AG1478 impaired replication of EMCV and HCV, but not that of an EMCV mutant previously shown to escape PI4KA inhibition. This work uncovers novel cellular and antiviral properties of AG1478, a compound previously only regarded as cancer chemotherapy agent.
Keywords
Coronacrisis-Taverne, SDG 3 - Good Health and Well-being
Citation
Dorobantu, C M, Harak, C, Klein, R, van der Linden, L, Strating, J R P M, van der Schaar, H M, Lohmann, V & van Kuppeveld, F J M 2016, 'Tyrphostin AG1478 inhibits encephalomyocarditis virus and hepatitis C virus by targeting phosphatidylinositol 4-kinase IIIα', Antimicrobial Agents and Chemotherapy, vol. 60, no. 10, pp. 6402-6406. https://doi.org/10.1128/AAC.01331-16